- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Cancer
Small charity eases struggles of breast cancer patients
October 6, 2012
Dan HumanWith volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients.
Recipients have ranged in age from 18 to 90.
MoreSledge's exit will keep IU program mostly intact
October 1, 2012
J.K. WallThe departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and
Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly
will remain intact.
MoreLilly wins appeal upholding patent for Alimta cancer drug
August 24, 2012
Bloomberg NewsEli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and
blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
MoreIndiana Blood Center tapping new vein of revenue
July 28, 2012
Mason KingGroup sees role in cellular therapy as growth area with profit margins higher than core business.
MoreLilly cancer treatment fails trial in stomach cancer
July 5, 2012
IBJ Staff and Bloomberg NewsErbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with
advanced stomach tumors in a late-stage clinical trial.
MoreCancer tools help Roche with Alzheimer's drug
May 13, 2012
Bloomberg NewsTreatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may
pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs
that attack the same protein as Roche’s experimental drug.
MoreWellPoint enrolls IBM supercomputer at IU medical school
April 21, 2012
J.K. WallIBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying
to teach it how to treat cancer.
MoreKomen grant recipients cope with controversy they didn't create
April 7, 2012
Kathleen McLaughlinLocal health care providers won’t find an easy replacement for the grant money supplied by Susan G. Komen for the Cure.
That money could be in jeopardy, as grass-roots Komen supporters appear to be sitting out of this year’s Race for the
Cure in response to a national controversy over grants to Planned Parenthood.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreNFP of NOTE: Little Red Door Cancer Agency
December 31, 2011
IBJ StaffLittle Red Door Cancer Agency strives to make the most of life and the least of cancer.
MoreQ&A
December 27, 2011
J.K. WallDr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
Q&A
December 5, 2011
J.K. WallCarmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier
for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating
officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he
thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreDebate rages over whether Lilly's Byetta lifts cancer risk
September 16, 2011
Bloomberg NewsA German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
MoreIU Cancer Center recruits top researcher
September 15, 2011
Scott OlsonDr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand
Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
MoreIU Health strikes deal with Central Indiana Cancer Centers
June 17, 2011
J.K. WallCentral Indiana Cancer Centers sold its five facilities to IU Health and transferred its 150 employees to the Indianapolis-based
hospital system. The 16 physicians in the practice will remain independent, but they have signed a service agreement with
IU Health that pulls the two entities into a tight embrace.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreRepeated price cuts take glow off Endocyte IPO
February 12, 2011
Greg AndrewsNew investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing
reveals.
MoreHead of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreGroup says billboard companies rejected anti-Lilly ad
November 3, 2010
Scott OlsonSan Francisco-based Breast Cancer Action wanted its message, "Eli Lilly is making us sick. Tell them to stop," posted on local
billboards. But numerous sign companies refused, the group said.
MoreCancer researcher battling Semafore in court
May 29, 2010
Chris O'MalleyFormer collaborator alleges firm breached its agreement with him and refused to pay royalty income.
MorePositron has billion-dollar hopes for medical-imaging scanner
May 29, 2010
J.K. WallA maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
MoreWellPoint pledges two-day hospital stays after mastectomy
May 26, 2010
J.K. WallIn the company's latest response to withering criticism of its breast-cancer policies, WellPoint Inc. said it will pay
for any breast cancer patient to stay two days in a hospital after surgery.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
RKW's comments read like a modern "Chicken Little". As a Raintree resident for many years, "Yes, I'm ready for this." Matter of fact, I welcome The Farm because it's a development that compliments our town, brings new and desirable shopping & dining closer (specialty grocer, upscale shops, micro brew pub, etc), offers upscale condos for empty nesters who want to stay in Zionsville, is being planned and constructed by local, well-reputed firms and, of course, provides desirable non property tax benefits. We all knew the Pittman's were going to develop their property sooner than later. That one of the Pittman's will continue to live on the property helps assure The Farm will be everything promised. This also sets a standard for other developers as to the quality of future developments - which should keep an ugly Walmart at bay for decades. As we've no meglomaniac mayor, I seriously doubt Zionsville would ever aspire to over-priced statues or subsidized retail rents. And we already have a very nice public theater, the Zionsville Performing Arts Center, that meets our cultural needs quite nicely.
Do we add (or subtract) these from the bounty we recieve from RTWFL, Daylight Savings Time, corporate tax giveaways, and the crack job IEDC is doing?? Or is Mike going to blame these on Mitch?
Who makes Tater Tots? They would be a good sponsor, because $3 Million for the alleged "Greatest Spectacle In Racing" is taters. Tiny, tiny taters. But at least they are making up something of the losses accumulated over the years in this dying sport. Buttock in seat is certainly not doing it, nor eyeball on TV, as evidenced by the lack of both.
We loved lakehouse and think the Arbor Village would be a great location. It is less than 2 miles from over 1000 rooftops in the 225,000 to over 1 million range. Many people could use the great fishers trail system to bike or walk there. Just an idea Scotty -- but maybe something closer to 3 Wiseman would good. The only microbrew in area is Ram (boring)
True, it's an ESPN production, but ESPN is just another name for ABC Sports, or what used to be ABC Sports since ABC Sports no longer exists as a name. ESPN=ABC Sports= ESPN. ESPN is, according to Forbes "the world's most valuable media property" worth $40 billion. Despite that, they fired 400 people this week.